Xeris Biopharma Holdings
XERS
225 hedge funds and large institutions have $791M invested in Xeris Biopharma Holdings in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 79 increasing their positions, 76 reducing their positions, and 40 closing their positions.
1,006% more call options, than puts
Call options by funds: $4.79M | Put options by funds: $433K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
4% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 76
0.77% more ownership
Funds ownership: 59.99% → 60.76% (+0.77%)
0% more capital invested
Capital invested by funds: $789M → $791M (+$2.84M)
2% less funds holding
Funds holding: 230 → 225 (-5)
10% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$13.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.7M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.87M |
| 5 |
BlackRock
New York
|
+$5.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.29M |
| 2 |
Renaissance Technologies
New York
|
-$7.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$6.9M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$6.42M |
| 5 |
Jane Street
New York
|
-$5.79M |
XERS Hedge Fund Activity: Q4 2025 in Review
225 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2025, worth a combined $791M — up 0.36% from $789M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of XERS and 36 opened new positions — a net loss of 4 holders — while 76 trimmed existing stakes and 79 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $13.7M. The largest seller was UBS Group, cutting an estimated $9.29M.
- 225 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2025, down from 230 in Q3 2025.
- Funds reported $791M of Xeris Biopharma Holdings stock for Q4 2025, up 0.36% quarter-over-quarter.
- 36 funds opened new Xeris Biopharma Holdings positions in Q4 2025 and 40 closed out, a net change of -4 holders.
- The largest Xeris Biopharma Holdings buyer in Q4 2025 was D.E. Shaw & Co, an estimated $13.7M added.
- The largest Xeris Biopharma Holdings seller in Q4 2025 was UBS Group, an estimated $9.29M sold.
Based on aggregated 13F filings for Q4 2025.